Clicky

Cannabis

Best Kratom Extracts: Label Checklist, Studies and Safety

What to check on a kratom extract label, what the human studies found, what federal agencies say about the legal status of kratom and 7-OH, and the side effects to know before you buy.

Short answer: this page doesn’t name a best kratom extract, because the things that decide “best” are things you can check yourself. Those are the product form, the alkaloids named on the label, a lab report tied to the batch you’re buying, the warnings, the age limit and the written return terms. Kratom is not FDA approved for any use, and the FDA says it is not lawfully marketed in the U.S. as a drug product, a dietary supplement or a food additive in conventional food.

Three different products get called kratom: leaf products, extracts, and products with added or concentrated 7-hydroxymitragynine (7-OH). This page covers leaf and extract products. The federal actions below mostly target the third group, and this page doesn’t recommend 7-OH products.

What is a kratom extract, compared with leaf?

Kratom is a tree, Mitragyna speciosa, native to Southeast Asia. Leaf products are made from the leaves. An extract is a more concentrated product, so its alkaloids (the plant’s active chemicals) make up a larger share of what’s in the package. The DEA’s kratom chemical profile lists the forms sold online as leaves (whole or crushed), powder, extract, encapsulated powder, and extract resin “pies” made from reduced extract.

Kratom contains over 50 alkaloids, according to the FDA’s kratom page. Most research focuses on two of them. Mitragynine is the most abundant, at about 66% of total alkaloid content. 7-hydroxymitragynine is a minor alkaloid, under 2% of total alkaloid content in the plant, according to the DEA profile and the FDA. That small share matters for labels, because a product with a lot of 7-OH is no longer a leaf product in the usual sense.

What does the number on an extract label mean?

Labels mix up several different units, and they don’t measure the same thing.

  • Product weight (grams of the package) tells you how much product you’re buying. It doesn’t tell you how much alkaloid is inside.
  • Percent mitragynine tells you the share of the product that is mitragynine. The 2026 extract blood-level study described its extract as 39.5% mitragynine.
  • Milligrams of mitragynine is an amount of the alkaloid itself. The same 2026 study reported its doses in milligrams of mitragynine, not in grams of product.
  • Ratio claims, such as “10:1,” are the maker’s number. They aren’t a measured alkaloid content.

Measured content varies a lot from product to product. A 2019 lab study quantified ten kratom alkaloids in leaf extracts, alkaloid-rich fractions, ethanolic extracts, lyophilized teas and commercial products. Mitragynine ranged from 0.7% to 38.7% (w/w) across the products it analyzed. That’s why a ratio or a strain name can’t tell you what’s in the bottle you’re holding. Only a lab test on that batch can.

Is kratom extract stronger than leaf?

The most direct study on this question is a 2026 blood-level study in humans, published in the Journal of Analytical Toxicology. It tested single doses and 15 daily doses of a concentrated kratom extract, and it measured mitragynine and 7-OH in the blood. The authors write that these data indicate concentrated kratom extracts “may yield greater overall mitragynine exposure than dried kratom leaf powder or kratom tea preparations administered at comparable doses.” That comparison is drawn against earlier studies of leaf powder and tea, not against a leaf arm inside this study.

That is one study of one extract. It isn’t a ranking of brands, and it doesn’t tell you which product is the strongest. The same paper says its half-life measurements were best at the higher doses and that the results suggested enzyme saturation was possible.

The authors also disclose that all of them are consultants to NP Pharma, LLC, and were compensated for writing the manuscript. Keep that in mind when you read the paper.

Is kratom an opioid or opiate?

Its main compounds act on the same brain receptors that opioid drugs act on. The NCCIH’s kratom overview says mitragynine and 7-hydroxymitragynine interact with opioid receptors in the brain. The FDA says both bind to the same mu-opioid receptors as opioid drugs such as codeine, and that 7-OH has substantially greater mu-opioid receptor potency than mitragynine and than morphine.

A receptor finding tells you what a compound can do in the brain. It doesn’t tell you how a particular person will feel or what will happen to them.

Is kratom an upper or a downer, and how long does it last?

It can be both. The NCCIH says people report stimulant-like effects, such as more energy, alertness and a faster heart rate, and also effects like those of opioids and sedatives, such as relaxation, pain relief and confusion. The DEA profile describes stimulant effects such as alertness and physical energy at low doses, and opioid effects including sedation and euphoria at high doses.

The DEA says kratom effects begin within 5 to 10 minutes after ingestion and last for 2 to 5 hours. That is the DEA’s general description of kratom, not a figure for extracts specifically.

Is kratom extract illegal, and can you go to jail for it?

Federal rules and state rules are different things, so start with the federal picture.

  • Kratom itself. The DEA says kratom is an unscheduled botanical and is not a controlled substance under the Controlled Substances Act. The NCCIH says the DEA lists it as a “drug of concern.” The FDA says kratom is not lawfully marketed in the U.S. as a drug product, a dietary supplement or a food additive in conventional food.
  • Related 7-OH compounds. The FDA’s 7-OH page says the DEA temporarily placed mitragynine pseudoindoxyl (MGPI), MGM-15 and MGM-16 into Schedule I on August 26, 2026.
  • Proposed 7-OH thresholds. The October 14, 2026 Federal Register notice is a notice of intent. It describes a threshold approach for 7-OH and MGPI: products above 1 milligram per gram in solid products or 1 milligram per milliliter in liquids, or with a mitragynine-to-7-OH ratio below 100 to 1, would be controlled in Schedule I. HHS says the threshold is meant to separate products intentionally enhanced with these substances from products whose alkaloid mix is more like botanical kratom. It’s a proposal, not a final scheduling action.

The FDA says states may have their own regulations or prohibitions for kratom products, and it names state health and law enforcement agencies as the best resource on state law. State and local rules differ, so check with your state health department or law enforcement agency.

Will a drug test pick up kratom?

Ask the testing lab or your employer which panel they run and whether that panel includes kratom alkaloids. The answer depends on the test, not on the product.

What is kratom called on the street?

Kratom itself is usually called kratom, or by its botanical name, Mitragyna speciosa. The DEA’s October 14, 2026 Federal Register notice lists names such as “7 Ohmz,” “7-hydroxy” and “7-OH” for products sold as 7-OH, and it says those products come as tablets, shots, capsules, powder, syrup, vapes, sublingual pouches or strips, nasal spray, chewables and liquid extracts. A product called a shot or a liquid extract can contain 7-OH, so the name alone doesn’t tell you what it is.

What are the bad side effects of kratom?

The NCCIH lists nausea, constipation, dizziness and drowsiness as mild effects that have been reported. The serious effects are rarer, but they are documented: seizures, high blood pressure and liver problems. The FDA warns about liver toxicity, seizures and substance use disorder.

Effect What the source says Source
Nausea, constipation, dizziness, drowsiness Reported mild effects NCCIH kratom overview
Seizures, high blood pressure, liver problems Reported rare but serious effects NCCIH kratom overview
Withdrawal after stopping regular use Regular users may experience withdrawal symptoms when they stop NCCIH kratom overview
Substance use disorder FDA reports cases that met criteria for substance use disorder, including cravings and continued use despite harm FDA kratom page
Newborn withdrawal FDA is aware of neonatal abstinence syndrome after prolonged exposure before birth FDA kratom page
Contamination Heavy metals and Salmonella found in some kratom products FDA kratom page; NCCIH overview
Deaths NCCIH says fatal overdoses from kratom alone appear to be extremely rare. FDA says deaths were usually linked to kratom combined with other drugs, and kratom’s contribution is unclear NCCIH overview; FDA kratom page
Combined with other drugs Linked to deaths and severe adverse effects such as liver problems NCCIH kratom overview

In the 2026 leaf powder safety trial, the most common side effects were dizziness, nausea and relaxation after single doses, and headache, feeling hot, raised liver enzyme (ALT) levels and nausea after repeated doses.

Poison-center data adds another angle. A CDC report counted 14,449 kratom exposure reports to poison centers from 2015 to 2025, and 3,434 of them came in 2025. That’s about 1,200% more than the 258 reports in 2015. These are reports, not rates of harm among all users. The data are voluntary and self-reported, and they don’t say whether the kratom involved was leaf or a concentrated 7-OH product.

For a broader safety guide, see super speciosa side effects.

What the human studies found

Human kratom research is still small. The FDA says there are few published reports from well-designed studies in which kratom was given to people. The studies below are the ones that matter most for an extract buyer. Each row lists the material tested: leaf powder, tea, pure mitragynine or a study extract.

Study Who took part What was given What it found Limit the paper states
2026, Journal of Analytical Toxicology: blood levels after extract Human participants Single escalating doses, then 15 daily doses, of a concentrated kratom extract that is 39.5% mitragynine Mitragynine peak levels rose with dose. Extract may yield greater mitragynine exposure than leaf powder or tea at comparable doses Half-lives were best measured at higher doses, and enzyme saturation was possible. All authors are consultants to NP Pharma, LLC
2026, Therapeutic Drug Monitoring: leaf powder safety trial 116 volunteers, 18 to 55 years old, randomized and placebo-controlled, with 49 receiving kratom Dried leaf powder: single doses, then 15 daily doses over 47 days No serious adverse events or deaths. The authors report it was well tolerated at the doses tested, with no evidence of meaningful abuse potential or withdrawal Applies to the leaf powder and the dose ranges tested
2026, Drug Testing and Analysis: abuse-potential study 116 healthy, kratom-naive adults (49 kratom, 67 placebo) Dried leaf powder in capsules: single dose, then 15 daily doses Subjective effects rose with dose and fell with repeated dosing. No one met the threshold for clinically meaningful opioid withdrawal. Adverse events were mostly mild The authors emphasize the importance of dose control and product standardization
2026, Journal of Clinical Psychopharmacology: pilot study 40 participants, recreational polydrug users with opioid experience Single doses of a leaf-based kratom with trace 7-OH, up to the highest dose tested Most common adverse events were somnolence, vomiting and nausea. The highest dose raised ratings of drug liking, good effects and high Single-sourced kratom. Results may not represent other kratom-containing products
2025, Psychopharmacology: mitragynine study 15 healthy volunteers in two groups Single doses of pure mitragynine, monitored for 7 hours The lowest dose raised ratings of arousal and attention. The highest dose raised ratings of amnesia and produced mild psychopathological symptoms Mitragynine did not affect most outcome measures at any dose. This is the pure compound, not a product
Drug-interaction study, PubMed Central 12 healthy adults A single low dose of kratom tea, with probe drugs for two liver enzymes Midazolam exposure rose modestly (geometric mean ratio 1.39). Dextromethorphan showed no change Co-consuming kratom with drugs extensively metabolized by CYP3A may precipitate serious interactions, the authors say

Lab studies of kratom extracts are a separate category, and they describe what happened in a dish, not in a body. A 2025 study in liver cells found leaf extracts from red-vein and white-vein strains increased LDL receptor protein and decreased PCSK9. A 2025 study in fat cells found an alkaloid-rich extract and mitragynine reduced lipid accumulation by up to 50 to 70% at non-cytotoxic concentrations. A 2024 study in immune cells found an alkaloid extract containing about 46% mitragynine inhibited COX-2 and 5-LOX enzymes, while a methanolic crude leaf extract containing about 5% mitragynine did not.

What to check on a kratom extract label

These are the things a buyer can verify. None of them is a ranking.

Check What to look for Why it matters
Product form Whether the label says leaf, powder, extract, or lists 7-OH, 7-hydroxymitragynine or MGPI The DEA’s Federal Register notice says 7-OH products are sold as tablets, shots, capsules, liquid extracts and other forms, so the form alone doesn’t identify the product
Named alkaloids Mitragynine listed, and whether 7-OH or MGPI is listed too An FDA safety alert on a liquid extract noted its label listed mitragynine and 7-OH
Ratio claim What the ratio is measured against A ratio is the maker’s number, and measured mitragynine ranged from 0.7% to 38.7% across the products in the 2019 study
Lab report for the batch A lab report matched to the lot number on your package It’s the way to check alkaloid numbers for the product you actually receive
Contaminants Whether the lab report includes heavy metals and bacteria The FDA has warned about Salmonella and heavy metal contamination in some kratom products
Health claims Whether the label says it treats pain, anxiety, depression, sleep, energy or withdrawal The FDA warns about false or misleading claims about unproven health benefits, and it has not approved kratom for any medical use
Warnings and age limit The warning text and minimum age printed on the label These are on the label itself, so read them before you buy
Return terms The seller’s written return policy Know what you’d have to send back and how long you have, before you order

Before you buy, search the product name on FDA’s safety alerts. In July 2024 the FDA warned consumers not to use OPMS Black Liquid Kratom, a liquid extract sold online and in some retail stores. It did so after receiving an adverse event report of a person who died after using it. The product label listed mitragynine and 7-OH.

Who should talk to a clinician first?

  • Pregnancy or breastfeeding. If you are pregnant or nursing, talk with a clinician before using kratom. The FDA is aware of newborn withdrawal signs after prolonged exposure before birth.
  • Prescription medicines. Kratom can interact with some drugs, as the drug-interaction study above found. The CDC report notes that kratom used with alcohol, opioids, benzodiazepines, stimulants and antidepressants might increase risk. Talk with a clinician or pharmacist about any medicine you take.
  • Liver disease. The NCCIH says there have been reports that long-term use of large doses of kratom may cause serious liver problems in some people. If you have liver disease, talk with a clinician first.
  • A history of substance use. The FDA reports cases of kratom-related substance use disorder, and the NCCIH says kratom itself may have the potential to be addictive. Talk with a clinician before you use it. If you’re thinking about stopping, the kratom withdrawal guide covers symptoms and how to get medical help.

If you have a bad reaction, report it to the FDA’s MedWatch program. The FDA’s kratom page lists the reporting options.

Before you order

  • Ask for the written return terms, including what you’d have to send back and how long you have to ask for a return.
  • Confirm whether the product contains 7-OH, 7-hydroxymitragynine or MGPI. This page doesn’t cover those products as a buying option.
  • Check your state and local rules with your state health department or law enforcement agency.

By HealthDataConsortium.org Research Team

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.